News
The histology of liver metastases from colon cancer could influence immunotherapy
A study by IDIBELL and ICO in collaboration with Uppsala University analyzes antitumor immune activity in encapsulated metastases compared to unencapsulated ones.
A worm model allows the study of adverse effects of the most common chemotherapy against solid tumors and improves its effectiveness
Using the earthworm C. elegans as a model, a group of researchers from IDIBELL and ICO has shown that a diet rich in glucose accentuates the effect of cisplatin and that dopamine protects against the neurotoxic effects of the drug.
The Biomedical Cluster receives the visit of Cristóbal Belda, director of the Carlos III Health Institute
The initiative wants to promote and consolidate this ecosystem located in the south of the Barcelona metropolitan area with the creation of new infrastructures and new services
The relevance of our female mentors
Today, February 11th is the International Day of Women and Girls in Science, and we want to highlight the importance of having mentors.
Convalescent plasma treatment against COVID-19 is not effective
The study shows no differences in complications that require hospitalization between people with COVID-19 who received intravenous plasma infusion and those who did not.
Scientists discover a micro-RNA that can promote the development of atherosclerosis in patients with coronary disease
The study opens the way to the potential use of inhibitors of this miRNA as a therapeutic strategy to stop the progression of this vascular condition
IDIBELL scientists take the stage in an All Stars edition of the sLHam
The IDIBELL science women sLHam reaches its 5th edition with the monologues of the most voted scientists women of the previous editions. The event will take place next Friday, February 11, at 7 pm in the Barradas Auditorium in l’Hospitalet.
The COVID-19 pandemic has affected the colorectal cancer screening: consequences of the first wave
Researchers from IDIBELL and ICO have analyzed the impact of the first COVID19 wave on the Colorectal Cancer Early Detection Program. The results show a 43% reduction in the number of invitations expected during 2020.